A new light-activated drug delivery method could help confine arthritis treatments to the joints, greatly reducing side effects. The drug is activated using an external, low-power laser shown here with a person’s finger (left) and the arthritic paw of a mouse (right).
CREDIT
Victoria Wickenheisser
Light helps arthritis treatments target joints
Although today’s rheumatoid arthritis treatments can reduce symptoms, they often come with serious side effects. Results from a new mouse study suggest that a new light-activated drug delivery method helps confine treatments to the joints, which could reduce whole-body side effects.
In the U.S., 1.3 million people are currently diagnosed with rheumatoid arthritis, a chronic disease that causes painful joint swelling that can eventually lead to bone loss and joint deformities.
“Our delivery system decreased arthritis in our experimental model while carrying and delivering much lower quantities of drug than is required for currently approved treatment,” said Emilia Zywot, a doctoral candidate from the University of North Carolina in Chapel Hill and member of the team that developed the new drug delivery approach.
Ms. Zywot was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.
For the new delivery approach, a drug is attached to vitamin B12 molecules that are engineered to respond to low levels of laser light. Transfusion is then used to deliver red blood cells loaded with the vitamin B12 molecules into mice, where the cells circulate until activated.
The drug is only activated in areas that receive a low level of long-wavelength laser light, which can be administered from outside the body. This controllable activation allows a high concentration of drug to be released at the site of inflammation, thus requiring overall lower whole-body, or systemic, amounts of the drug for effective treatment.
To test their new method, the researchers administered the arthritis drug dexamethasone to arthritic mice via traditional injections and the light-based delivery system. Laser light was used to activate the light-responsive drug in an arthritic paw. They found that the light-based delivery system decreased arthritis using a three-fold lower dose of dexamethasone.
“We hope that our drug delivery platform will better control drug delivery and decrease the amount of systemic exposure and off-target effects,” said Ms. Zywot. “We envision that it will be useful for any drug that can be synthetically attached to our light-responsive system, making it amenable to applications beyond arthritis.”
The researchers plan to further investigate the light responsive drug delivery system in mouse models of arthritis to better understand efficacy of the new system compared to current treatments.
Although today’s rheumatoid arthritis treatments can reduce symptoms, they often come with serious side effects. Results from a new mouse study suggest that a new light-activated drug delivery method helps confine treatments to the joints, which could reduce whole-body side effects.
In the U.S., 1.3 million people are currently diagnosed with rheumatoid arthritis, a chronic disease that causes painful joint swelling that can eventually lead to bone loss and joint deformities.
“Our delivery system decreased arthritis in our experimental model while carrying and delivering much lower quantities of drug than is required for currently approved treatment,” said Emilia Zywot, a doctoral candidate from the University of North Carolina in Chapel Hill and member of the team that developed the new drug delivery approach.
Ms. Zywot was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.
For the new delivery approach, a drug is attached to vitamin B12 molecules that are engineered to respond to low levels of laser light. Transfusion is then used to deliver red blood cells loaded with the vitamin B12 molecules into mice, where the cells circulate until activated.
The drug is only activated in areas that receive a low level of long-wavelength laser light, which can be administered from outside the body. This controllable activation allows a high concentration of drug to be released at the site of inflammation, thus requiring overall lower whole-body, or systemic, amounts of the drug for effective treatment.
To test their new method, the researchers administered the arthritis drug dexamethasone to arthritic mice via traditional injections and the light-based delivery system. Laser light was used to activate the light-responsive drug in an arthritic paw. They found that the light-based delivery system decreased arthritis using a three-fold lower dose of dexamethasone.
“We hope that our drug delivery platform will better control drug delivery and decrease the amount of systemic exposure and off-target effects,” said Ms. Zywot. “We envision that it will be useful for any drug that can be synthetically attached to our light-responsive system, making it amenable to applications beyond arthritis.”
The researchers plan to further investigate the light responsive drug delivery system in mouse models of arthritis to better understand efficacy of the new system compared to current treatments.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Rheumatoid arthritis
- What Is Psoriatic Arthritis? 3 MDs Weigh In
About 30 percent of people with psoriasis will develop psoriatic arthritis. Here's what to know about symptoms and treatment.
- Cracking Knuckles Causes Arthritis And Other Common Myths Debunked
Did you know that there are more than 100 types of arthritis, each with its own unique characteristics that end up affecting the joints? Osteoarthritis and Rheumatoid arthritis (RA) are some of the ...
- Arthritis Foundation Encourages Patients to Mark Arthritis Awareness Month by Sharing Words That Inspire Them on Their Journey
"In reality, many types of arthritis, such as psoriatic and rheumatoid arthritis, are caused by autoimmune dysfunction. And while it's true that osteoarthritis can be caused by wear and tear of the ...
- Patients with rheumatoid arthritis have unique and complex autoantibody patterns, study reveals
Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease. Researchers at Utrecht University unveiled the complexity ...
- Rheumatoid Arthritis Patients Have Unique Autoantibody Patterns
Patients with rheumatoid arthritis (RA) all have a unique and diverse set of antibodies that are involved in the development of the disease. Researchers at Utrecht University unveiled the complexity ...
Go deeper with Google Headlines on:
Rheumatoid arthritis
[google_news title=”” keyword=”rheumatoid arthritis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Light-activated drug delivery
- Researchers develop tiny droplets that harness laser light to detect disease markers
A team of researchers led by Nanyang Technological University, Singapore (NTU Singapore) has created tiny droplets that, when activated by laser light, can detect viral protein biomarkers indicating ...
- Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie ...
- Microdroplets harness laser light to detect disease markers
The microdroplets could be applied in photodynamic therapy, where patients receive a light-activated drug. These drugs, called photosensitisers, are designed to be absorbed only by diseased or ...
- Sanofi gets grant for optical decoding system for determining medicament dose in drug delivery device
Enhance medication dosing accuracy with Sanofi's patented optical decoding system for drug delivery devices. Improve efficiency and precision in dispensing with this innovative technology.
- MIT Technology Review
Polina Anikeeva, PhD ’09, followed up her ultrathin brain probes with tools to study the gut-brain connection—and now leads an MIT research center investigating neural pathways throughout the body.
Go deeper with Google Headlines on:
Light-activated drug delivery
[google_news title=”” keyword=”light activated drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]